These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 21978631

  • 21. Vasomotor menopausal symptoms are associated with increased risk of coronary heart disease.
    Gast GC, Pop VJ, Samsioe GN, Grobbee DE, Nilsson PM, Keyzer JJ, Wijnands-van Gent CJ, van der Schouw YT.
    Menopause; 2011 Feb; 18(2):146-51. PubMed ID: 21127438
    [Abstract] [Full Text] [Related]

  • 22. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study.
    Chang SC, Lacey JV, Brinton LA, Hartge P, Adams K, Mouw T, Carroll L, Hollenbeck A, Schatzkin A, Leitzmann MF.
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):723-30. PubMed ID: 17416763
    [Abstract] [Full Text] [Related]

  • 23. Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study.
    Løkkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Hundrup YA, Obel EB, Pedersen AT.
    Arch Neurol; 2003 Oct; 60(10):1379-84. PubMed ID: 14568807
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Age at menarche and risk of vasomotor menopausal symptoms: a pooled analysis of six studies.
    Chung HF, Zhu D, Dobson AJ, Kuh D, Gold EB, Crawford SL, Avis NE, Mitchell ES, Woods NF, Anderson DJ, Mishra GD.
    BJOG; 2021 Feb; 128(3):603-613. PubMed ID: 33135854
    [Abstract] [Full Text] [Related]

  • 26. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
    Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA.
    Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
    [Abstract] [Full Text] [Related]

  • 27. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms.
    Lindh-Astrand L, Bixo M, Hirschberg AL, Sundström-Poromaa I, Hammar M.
    Menopause; 2010 Aug; 17(1):72-9. PubMed ID: 19675505
    [Abstract] [Full Text] [Related]

  • 28. Duration of vasomotor symptoms in middle-aged women: a longitudinal study.
    Col NF, Guthrie JR, Politi M, Dennerstein L.
    Menopause; 2009 Aug; 16(3):453-7. PubMed ID: 19188852
    [Abstract] [Full Text] [Related]

  • 29. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study.
    Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K.
    Menopause; 2008 Aug; 15(1):51-8. PubMed ID: 18257142
    [Abstract] [Full Text] [Related]

  • 30. Standard and low-dose hormone therapy for postmenopausal women--focus on the breast.
    Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC.
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):127-34. PubMed ID: 17638620
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.
    Rossouw JE, Manson JE, Kaunitz AM, Anderson GL.
    Obstet Gynecol; 2013 Jan; 121(1):172-6. PubMed ID: 23262943
    [Abstract] [Full Text] [Related]

  • 33. Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study.
    Du Y, Scheidt-Nave C, Schaffrath Rosario A, Ellert U, Dören M, Knopf H.
    Climacteric; 2009 Aug; 12(4):329-40. PubMed ID: 19437194
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women.
    Sidelmann JJ, Skouby SO, Vitzthum F, Schwarz H, Jespersen J.
    Climacteric; 2010 Aug; 13(4):340-6. PubMed ID: 20222844
    [Abstract] [Full Text] [Related]

  • 37. Progesterone for hot flush and night sweat treatment--effectiveness for severe vasomotor symptoms and lack of withdrawal rebound.
    Prior JC, Hitchcock CL.
    Gynecol Endocrinol; 2012 Oct; 28 Suppl 2():7-11. PubMed ID: 22849758
    [Abstract] [Full Text] [Related]

  • 38. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS).
    Shlipak MG, Chaput LA, Vittinghoff E, Lin F, Bittner V, Knopp RH, Hulley SB, Heart and Estrogen/progestin Replacement Study Investigators.
    Am Heart J; 2003 Nov; 146(5):870-5. PubMed ID: 14597937
    [Abstract] [Full Text] [Related]

  • 39. Menopausal hormone therapy (HT) in patients with breast cancer.
    Batur P, Blixen CE, Moore HC, Thacker HL, Xu M.
    Maturitas; 2006 Jan 20; 53(2):123-32. PubMed ID: 16368466
    [Abstract] [Full Text] [Related]

  • 40. Self-reported anxiety, depressive, and vasomotor symptoms: a study of perimenopausal women presenting to a specialized midlife assessment center.
    Seritan AL, Iosif AM, Park JH, DeatherageHand D, Sweet RL, Gold EB.
    Menopause; 2010 Mar 20; 17(2):410-5. PubMed ID: 20216277
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.